Investigators surveyed stakeholders involved in TB programmes, civil society and clinical care to gauge receptivity to long-acting injectables for tuberculosis. The cohort from Survey A indicated substantial overall favourability: combined with Survey B results, 83% of respondents preferred LAIs to standard oral TB regimens. The study team analysed survey responses with descriptive statistics and ordinal logistic regression, and then used purposive sampling to invite respondents into follow-up focus group discussions (FGDs) designed to explain quantitative patterns.
Survey A targeted decision-makers and frontline professionals. These respondents provided program-level and clinical perspectives on operational feasibility, acceptability and likely barriers to adoption. The article reports aggregated findings rather than itemised responses by stakeholder subgroup in the abstract; readers should consult the full text for detailed subgroup breakdowns.
Community members and people affected by TB (Survey B) formed the larger sample and drove much of the acceptability signal. The cohort showed heterogeneous interest: overall preference for LAIs remained high, but the study team observed lower interest among participants with lived TB experience compared with those without such experience. Focus group narratives suggested that previous negative encounters with injectable formulations—pain, side effects, or poor counselling—may have reduced enthusiasm in this subgroup.
FGDs enabled investigators to link these quantitative differences to specific lived concerns. Participants with prior TB described trust and prior-treatment context as shaping future choices. The preprint provides illustrative quotations and summary findings; granular demographic or subgroup counts for the FGDs are included in the full manuscript and supplementary material rather than in the abstract.
The surveys presented specific hypothetical regimens and compared them with six months of daily oral treatment. When offered a three-month regimen consisting of one month of daily oral therapy followed by monthly clinic visits, 69% of respondents preferred the option that included one injection per monthly visit for two months rather than continuing daily oral therapy for six months. A larger share—80%—preferred the alternate three-month regimen that involved two injections per clinic visit.
The investigators did not report pharmacologic dosing or specific LAI formulations in the abstract. The comparisons reflect stated preferences for delivery frequency and visit schedule rather than trial-evaluated efficacy or safety outcomes for specific long-acting agents.
For TB prevention, respondents were asked to choose between a single injection and one month of oral preventive therapy. Seventy-nine percent preferred a single injection as the preventive option. That preference suggests potential acceptability of LAI modalities in the preventive setting, pending clinical evidence for efficacy, safety and duration of protection—details that the abstract does not provide.
The FGD analysis used a modified framework approach to extract themes that clarified survey responses. Several themes emerged: previous negative experiences with injectables shaped skepticism among people with lived TB; concerns about side effects and the permanence or long pharmacokinetic tail of an injectable were commonly voiced; convenience and reduced pill burden motivated many respondents to favour LAIs. The study team reported these themes as explanatory context for the numerical results.
Participants emphasised choice and agency. The cohort expressed conditional acceptance—willingness to consider LAIs if safety information, clear counselling and options were available. The preprint includes illustrative quotations; readers should consult the manuscript for complete thematic tables and verbatim excerpts.
This investigation used a sequential explanatory mixed-methods design: online surveys followed by FGDs. Survey A sampled TB programme managers, civil society members and healthcare workers; Survey B sampled community members and persons affected by TB. Purposive sampling recruited FGD participants from survey respondents. Quantitative analyses included descriptive statistics, one-sample proportion tests and ordinal logistic regression with stepwise AIC selection. Qualitative transcripts were analysed with a modified framework analysis.
The authors reported ethical approvals from the WCG Institutional Review Board (IRB Protocol #: 20252075) and the London School of Hygiene & Tropical Medicine Research Ethics Committee (LSHTM Ethics Ref: 33795). Funding sources named in the preprint include the Gates Foundation, Unitaid and the Medical Research Council.
The manuscript is a medRxiv preprint and has not been peer reviewed; investigators noted that detailed product-level information—such as specific LAI agents, dosing regimens, efficacy data and safety profiles—was not provided in the abstract. The study relied on stated preferences and hypothetical regimens rather than exposure to licensed LAI products. Implementation questions remain: how prior negative experiences with injectable therapies can be mitigated, what counselling and consent models will preserve patient agency, and how preferences translate into real-world uptake when efficacy and safety data for specific LAIs are available.
The study ends by indicating that product development and implementation strategies should address injectable-related concerns and side-effect anxieties while preserving choice; specific regulatory milestones, product dossiers or trial endpoints are not reported in the abstract and would require review of the full text and supplementary material for further detail.